OPEN ACCESS: Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program
https://t.co/FaiBIEEGki
#Cardiology
Patient #100 randomized in Empire Prevent
Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): a randomized controlled trial.
Collaboration between @CardResearchOuh and @HGHHjerte.